Gender and survival in malignant tumours.

Abstract:

BACKGROUND:Epidemiological evidence supports the existence of a survival advantage for female patients with melanoma. This survival advantage often persists when other prognostic variables are taken into account. The basis for this female advantage or male disadvantage is not established although female sex steroids can retard melanoma invasion in vitro. DESIGN:In considering the mechanisms involved, we have examined the literature to establish whether this female survival advantage is shared by other solid tumours. The tumours selected were breast, lung, colorectal, oesophageal, gastric, pancreatic and soft tissue sarcoma. A Medline database search was carried out to identify those studies in which gender was investigated as a prognostic indicator. RESULTS:Results from large, mostly retrospective series show that for 5 of these 7 tumour groups, there is evidence for a female survival advantage. In particular, this survival advantage is usually more prominent in early stage disease. CONCLUSION:Melanoma is not unique in showing a female survival advantage. Although the current literature does not address the mechanisms involved, we suggest that these are worth investigating as they may contribute to new treatment modalities aimed at preventing metastatic spread.

journal_name

Cancer Treat Rev

journal_title

Cancer treatment reviews

authors

Molife R,Lorigan P,MacNeil S

doi

10.1053/ctrv.2001.0220

keywords:

subject

Has Abstract

pub_date

2001-08-01 00:00:00

pages

201-9

issue

4

eissn

0305-7372

issn

1532-1967

pii

S0305-7372(01)90220-8

journal_volume

27

pub_type

杂志文章,评审
  • Targeting uPA/uPAR in prostate cancer.

    abstract::Prostate cancer (CaP) is one of the most common malignancies in men, with an increasing incidence. Despite significant advances in surgery, chemotherapy and radiotherapy to treat CaP, many patients unfortunately succumb to secondary disease (metastases). The invasive ability of tumour cells plays a key role in CaP met...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2007.06.003

    authors: Li Y,Cozzi PJ

    更新日期:2007-10-01 00:00:00

  • Prognostic value of lymphocyte-to-monocyte ratio in patients with solid tumors: A systematic review and meta-analysis.

    abstract:BACKGROUND:The immune system plays an important role in cancer pathogenesis. A low lymphocyte-to-monocyte ratio (LMR), as a simple biomarker of host immune system, has been suggested to be related to poor prognosis in various cancers. We performed a systematic review and meta-analysis to quantify the prognostic value o...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/j.ctrv.2015.10.003

    authors: Nishijima TF,Muss HB,Shachar SS,Tamura K,Takamatsu Y

    更新日期:2015-12-01 00:00:00

  • Beyond BRCA: new hereditary breast cancer susceptibility genes.

    abstract::Approximately 5-10% of breast cancer cases might be inheritable, up to 30% of which are due to BRCA1/2 mutations. During the past few years and thanks to technology evolution, we have been witnesses of an intensive search of additional genes with similar characteristics, under the premise that successful gene discover...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2014.10.008

    authors: Economopoulou P,Dimitriadis G,Psyrri A

    更新日期:2015-01-01 00:00:00

  • New developments in arc radiation therapy: a review.

    abstract::Arc therapies have gained widespread clinical interest in radiation oncology over the past decade. Arc therapies have several potential advantages over standard techniques such as intensity-modulated radiation therapy, with implications for patients, administrators, and oncologists. This review focuses on the rational...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2010.01.004

    authors: Palma DA,Verbakel WF,Otto K,Senan S

    更新日期:2010-08-01 00:00:00

  • Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors.

    abstract::The first-generation epidermal growth factor receptor tyrosine kinase inhibitors erlotinib and gefitinib have been incorporated into treatment paradigms for patients with advanced non-small cell lung cancer. These agents are particularly effective in a subset of patients whose tumors harbor activating epidermal growth...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2011.01.003

    authors: Giaccone G,Wang Y

    更新日期:2011-10-01 00:00:00

  • The use of haemoregulatory peptides (pEEDCK monomer and dimer) for reduction of cytostatic drug induced haemopoietic damage.

    abstract::We have previously shown that the stem cell inhibitory peptide pGlu-Glu-Asp-Cys-Lys (pEEDCK monomer) leads to a good tolerance of otherwise lethal multiple ara-C doses and an increased survival of ara-C + peptide treated mice. This effect was due to the prevention of drug-induced CFU-S proliferation, thus keeping stem...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/0305-7372(90)90068-q

    authors: Paukovits WR,Moser MH,Binder KA,Paukovits JB

    更新日期:1990-09-01 00:00:00

  • Alternative formulations of paclitaxel.

    abstract::Paclitaxel, a novel antitumour agent, is active clinically against advanced ovarian and breast cancer and under investigation for various other cancers. One of the problems associated with the intravenous administration of paclitaxel is its low solubility in water. The current pharmaceutical formulation consists of a ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/s0305-7372(97)90022-0

    authors: Terwogt JM,Nuijen B,Huinink WW,Beijnen JH

    更新日期:1997-03-01 00:00:00

  • Microtubule stabilizing agents: their molecular signaling consequences and the potential for enhancement by drug combination.

    abstract::Microtubule stabilization by chemotherapy is a powerful weapon in the war against cancer. Disruption of the mitotic spindle activates a number of signaling pathways, with consequences that may protect the cell or lead to its death via apoptosis. Taxol, the first microtubule stabilizing drug to be identified, has been ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2006.01.004

    authors: Bergstralh DT,Ting JP

    更新日期:2006-05-01 00:00:00

  • Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib.

    abstract::Given its role in cellular metabolism, the proteasome could prove to be a critical target that can be exploited in treating cancer. In preclinical studies, several mechanisms for bortezomib's activity in multiple myeloma cells have been identified (e.g., NF-kappaB inhibition); antitumor activity with bortezomib has be...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/s0305-7372(03)00079-3

    authors: Cusack JC

    更新日期:2003-05-01 00:00:00

  • Patient-controlled analgesia (PCA) in the domiciliary care of tumour patients.

    abstract::Patient-controlled analgesia (PCA) was administered in the domiciliary environment in 143 pre-terminally and terminally ill tumour patients suffering either from excruciating chronic pain or severe chronic/acute complex pain that could not be relieved adequately by oral analgesia. Morphine solutions were infused subcu...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章

    doi:10.1016/s0305-7372(96)90076-6

    authors: Meuret G,Jocham H

    更新日期:1996-01-01 00:00:00

  • Swallowing dysfunction in head and neck cancer patients treated by radiotherapy: review and recommendations of the supportive task group of the Italian Association of Radiation Oncology.

    abstract:PURPOSE:Dysphagia is a debilitating complication in head and neck cancer patients (HNCPs) that may cause a high mortality rate for aspiration pneumonia. The aims of this paper were to summarize the normal swallowing mechanism focusing on its anatomo-physiology, to review the relevant literature in order to identify the...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2012.04.002

    authors: Russi EG,Corvò R,Merlotti A,Alterio D,Franco P,Pergolizzi S,De Sanctis V,Ruo Redda MG,Ricardi U,Paiar F,Bonomo P,Merlano MC,Zurlo V,Chiesa F,Sanguineti G,Bernier J

    更新日期:2012-12-01 00:00:00

  • The metabolic syndrome in long-term cancer survivors, an important target for secondary preventive measures.

    abstract::With increasing numbers of cancer survivors, attention has been drawn to long-term complications of curative cancer treatment, including a range of metabolic disorders. These metabolic disorders often resemble the components of the so-called metabolic syndrome, or syndrome X, which is an important risk factor for the ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/s0305-7372(02)00038-5

    authors: Nuver J,Smit AJ,Postma A,Sleijfer DT,Gietema JA

    更新日期:2002-08-01 00:00:00

  • Intraperitoneal chemotherapy in ovarian cancer.

    abstract::From a theoretical viewpoint, intraperitoneal therapy (IP) in patients with ovarian cancer, a malignancy which remains mainly confined to the peritoneal cavity, is logical. Over the past decades this approach has evolved into a therapeutic strategy for a selected group of patients. Data available at present suggest a ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章

    doi:10.1053/ctrv.1999.0152

    authors: Hofstra LS,de Vries EG,Mulder NH,Willemse PH

    更新日期:2000-04-01 00:00:00

  • Open conservation partial laryngectomy for laryngeal cancer: a systematic review of English language literature.

    abstract:BACKGROUND:Different modalities of treatment in early laryngeal cancer lead to equivalent oncological outcomes. Hence this systematic review was undertaken to synthesise the key oncological outcomes following primary open partial laryngectomy for laryngeal cancer. METHODS:A systematic review of the English literature ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/j.ctrv.2011.05.010

    authors: Thomas L,Drinnan M,Natesh B,Mehanna H,Jones T,Paleri V

    更新日期:2012-05-01 00:00:00

  • The potential of melanoma antigen expression in cancer therapy.

    abstract::A potential new therapy for cancer is active specific immunotherapy with melanoma antigen (MAGE) gene products. The MAGE gene family comprizes a series of 12 closely related genes, some of which have been shown to be expressed in a variety of tumours of different histological origin. Peptides encoded by the MAGE genes...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1053/ctrv.1999.0126

    authors: Gillespie AM,Coleman RE

    更新日期:1999-08-01 00:00:00

  • PD-1 and PD-L1 blockade in gastrointestinal malignancies.

    abstract::Immunotherapy represents a major breakthrough in cancer therapy in recent years. Immune-checkpoint blockade using PD-1 and PD-L1 antibodies appears to be one of the most promising immunotherapy approaches. Immunotherapy differs from conventional cancer treatment because of its ability to produce durable responses in s...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2015.09.004

    authors: Lote H,Cafferkey C,Chau I

    更新日期:2015-12-01 00:00:00

  • Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy.

    abstract::The prognosis of advanced pancreatic adenocarcinoma is still poor nowadays. Gemcitabine in monotherapy (30-min infusion) has been the standard of treatment during the last decade, and many clinical trials have failed to demonstrate an improvement in overall survival (OS) with the addition of different drugs to gemcita...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2008.11.007

    authors: Rivera F,López-Tarruella S,Vega-Villegas ME,Salcedo M

    更新日期:2009-06-01 00:00:00

  • Cardiac toxicity in breast cancer patients: from a fractional point of view to a global assessment.

    abstract::When focusing on heart disease, most available studies split the two different parts of the adjuvant treatment, i.e., systemic therapies and radiation therapy, making it difficult to implement efficient strategies for preventing treatment-induced cardiac toxicity. This paper reviews the current understanding of treatm...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2010.08.007

    authors: Chargari C,Kirov KM,Bollet MA,Magné N,Védrine L,Cremades S,Beuzeboc P,Fourquet A,Kirova YM

    更新日期:2011-06-01 00:00:00

  • p53 as a target for the treatment of cancer.

    abstract::TP53 (p53) is the most frequently mutated gene in cancer, being altered in approximately 50% of human malignancies. In most, if not all, cancers lacking mutation, wild-type (WT) p53 is inactivated by interaction with cellular (MDM2/MDM4) or viral proteins, leading to its degradation. Because of its near universal alte...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2014.10.004

    authors: Duffy MJ,Synnott NC,McGowan PM,Crown J,O'Connor D,Gallagher WM

    更新日期:2014-12-01 00:00:00

  • Cancer stem cells niche: a target for novel cancer therapeutics.

    abstract::Nowadays, cancer has been a frequent disease, and the first or second most common cause of death worldwide. Despite a better understanding of the biology of cancer cells, the therapy of most cancers has not significantly changed for the past four decades. It is because conventional chemotherapies and/or radiation ther...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2012.10.004

    authors: Yi SY,Hao YB,Nan KJ,Fan TL

    更新日期:2013-05-01 00:00:00

  • Is there a role for a specialized follow-up clinic for survivors of pediatric cancer?

    abstract::Due to advances in chemotherapy and supportive care, greater than 70% of patients with childhood cancer will survive 5 years. However, there are long-term physiological and psychological sequelae of these treatments that may not manifest until pediatric survivors are into adulthood. Various studies done in the long-te...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2010.02.014

    authors: Prasad PK,Bowles T,Friedman DL

    更新日期:2010-06-01 00:00:00

  • Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications.

    abstract::In cancer biology angiogenesis plays a vital role in tumour growth and its subsequent metastatic potential. By targeting the angiogenic process, a new treatment strategy was added in the clinician's therapeutic armamentarium. On the other hand, numerous classic cytotoxic agents are currently considered as potential an...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2011.09.002

    authors: Soultati A,Mountzios G,Avgerinou C,Papaxoinis G,Pectasides D,Dimopoulos MA,Papadimitriou C

    更新日期:2012-08-01 00:00:00

  • Maintenance treatment of recurrent ovarian cancer: Is it ready for prime time?

    abstract::Approximately 1% of women in the United States will be diagnosed with epithelial ovarian cancer (EOC) during their lifetime. It is most likely to present at a more advanced stage, requiring aggressive therapeutic measures, and most women will succumb to this illness. Due to advancements in therapy, the oncology commun...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2018.06.001

    authors: DiSilvestro P,Alvarez Secord A

    更新日期:2018-09-01 00:00:00

  • Branchiogenic carcinoma--conceptual or true clinico-pathological entity?

    abstract::The existence of branchiogenic carcinoma remains controversial. According to some authors, this malignancy is more conceptual than a true clinicopathologic entity. The originally proposed diagnostic criteria of branchiogenic carcinoma have been subsequently challenged. Many reports regarding primary branchiogenic carc...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2004.12.007

    authors: Jereczek-Fossa BA,Casadio C,Jassem J,Luzzatto F,Viale G,Bruschini R,Chiesa F,Orecchia R

    更新日期:2005-04-01 00:00:00

  • Fertility preservation in cancer patients: the global framework.

    abstract::Cancer treatment is the most frequent cause of reduced fertility in cancer patients, with up to 80% of survivors affected. None of the established or experimental fertility preservation methods can assure parenthood, rather they may provide a future opportunity to overcome treatment induced sterility. Around 70-75% of...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2014.06.001

    authors: Linkeviciute A,Boniolo G,Chiavari L,Peccatori FA

    更新日期:2014-09-01 00:00:00

  • CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy.

    abstract::Chemokines are proteins which induce chemotaxis, promote differentiation of immune cells, and cause tissue extravasation. Given these properties, their role in anti-tumor immune response in the cancer environment is of great interest. Although immunotherapy has shown clinical benefit for some cancer patients, other pa...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2017.11.007

    authors: Tokunaga R,Zhang W,Naseem M,Puccini A,Berger MD,Soni S,McSkane M,Baba H,Lenz HJ

    更新日期:2018-02-01 00:00:00

  • The management of women at high risk for the development of breast cancer: risk estimation and preventative strategies.

    abstract::Despite recent progress in the diagnostic and therapeutic approaches to the management of women with breast cancer, at least one third of these women will ultimately die from their disease. This resulted in a new focus on breast cancer prevention, especially for the woman designed as "high-risk". The continuing challe...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/s0305-7372(02)00107-x

    authors: Sakorafas GH

    更新日期:2003-04-01 00:00:00

  • Differential expression of drug resistance following in vitro exposure of human tumour cell lines to fractionated X-irradiation.

    abstract::We have established that drug resistance can be expressed following in vitro exposure of tumour cells not only to antitumor drugs but also to fractionated X-irradiation. These data therefore suggest a biological basis for the clinical problem of drug resistance that can occur in patients with previously irradiated tum...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章

    doi:10.1016/0305-7372(90)90012-5

    authors: Hill BT,Whelan RD,Hosking LK,Bedford P,Dempke WC,Shellard SA

    更新日期:1990-12-01 00:00:00

  • Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma.

    abstract::Hodgkin lymphoma is a B cell derived malignancy characterized by a low number of tumor cells within an environment consisting of inflammatory cells. Recently, immune checkpoint blockade targeting the PD-1-PD-L1 axis has shown to be a great success in relapsed and refractory Hodgkin lymphoma patients. However, complete...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2019.101931

    authors: Veldman J,Visser L,Berg AVD,Diepstra A

    更新日期:2020-01-01 00:00:00

  • Estrogen receptor-negative progesterone receptor-positive breast cancer - "Nobody's land" or just an artifact?

    abstract::The estrogen receptor α (ER) and the progesterone receptor (PgR) are one of the most important prognostic and predictive immunohistochemical markers in breast cancer. Breast cancers may express various profiles of hormone receptors: ER(+)/PgR(+), ER(-)/PgR(-), ER(+)/PgR(-) and ER(-)/PgR(+). The existence of the latter...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2018.05.005

    authors: Kunc M,Biernat W,Senkus-Konefka E

    更新日期:2018-06-01 00:00:00